Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.
Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine.
复制标题
DOI：
10.1016/j.lrr.2014.03.002
复制
发表时间：
2014-01-01
影响因子：
--
通讯作者：
Bessho, Masami
中科院分区：
文献类型：
--
作者：
Okamura, Daisuke;Matsuda, Akira;Bessho, Masami
骨髓增生异常综合征伴骨髓纤维化(MDS-F)是一种预后较差的造血系统疾病。阿扎替丁被证明可以延长高危MDS患者的生存时间。然而，氮杂西汀对MDS-F的影响尚不清楚。阿扎替丁治疗1例74岁MDS-F患者，每日皮下注射75 mg/m(2)，每28天1次，疗程7天。治疗8个周期后，根据国际工作组2006标准观察血液学改善情况，14个周期后血液学完全缓解。骨髓纤维化程度也有所改善。阿扎替丁的治疗活性在我们的MDS-F患者中得到证实。
Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was administered to a 74-year-old man with MDS-F at a dose of 75mg/m(2)/daily subcutaneously for 7days every 28days. Hematologic improvements were observed according to the International Working Group 2006 criteria after 8 cycles of the azacitidine treatment, and complete remission was achieved after 14 cycles. The grade of myelofibrosis was also improved. The therapeutic activity of azacitidine was confirmed in our MDS-F patient.